Clinical trials: PD-1 Inhibitors
Stomach Adenocarcinoma, Gastro-esophageal Junction Cancer
Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of the multimodal treatment, which includes radiotherapy, chemotherapy and anti-PD-1 immunotherapy. The trial is designed using a pick-the-winner strategy.
- Trial name
- TORCH-G (NCT06728657)
- Testing
- HFRT targeted to the primary lesion and positive lymph nodes, PULSAR targeted to the primary lesion and positive lymph nodes, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Plaque, Atherosclerotic, Immune Checkpoint Inhibitors
A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
- Conditions
- Plaque, Atherosclerotic, Immune Checkpoint Inhibitors, Programmed Cell Death Protein 1 Inhibitor, Carotid Artery Plaque
- Trial name
- NCT05123287
- Testing
- PD-1 immune checkpoint blockades
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neoadjuvent, PD-1 Inhibitor
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
The aim of this study was to investigate the efficacy and safety of pembrolizumab combined with albumin paclitaxel and cisplatin versus albumin paclitaxel and cisplatin or 5-fluorouracil and cisplatin in neoadjuvant therapy for…
- Conditions
- Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06006650
- Testing
- Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 114 people
- Sponsor
- Tang-Du Hospital
Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant immunochemotherapy (NAIC) has demonstrated promising pathological and survival outcomes in patients with resectable locally advanced oral and oropharyngeal squamous cell carcinoma (LA-OSCC/OPSCC).
- Trial name
- NCT07457099
- Testing
- Observation, Postoperative Radiotherapy, PD-1 Inhibitor Maintenance Therapy
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Zhujiang Hospital
HNSCC, Radiotherapy
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
In patients with locally advanced head and neck squamous cell carcinoma undergoing standard surgical treatment after neoadjuvant immunochemotherapy, can PD-1 inhibitor therapy be used instead of adjuvant radiotherapy for both…
- Conditions
- HNSCC, Radiotherapy, PD-1
- Trial name
- HNC-SYSU-003 (NCT05980715)
- Testing
- PD-1inhibitor, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 324 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Colorectal Cancer
Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer
This randomized phase II trial evaluates the efficacy of long-course chemoradiotherapy (50Gy/25Fx + capecitabine) versus short-course radiotherapy (25Gy/5Fx) combined with CAPOX（Capecitabine and Oxaliplatin）, PD-1 inhibitor…
- Trial name
- NCT07154316
- Testing
- LCRT, SCRT, CAPOX
- Where
- 5 sites in China
- Volunteers
- 138 people
- Sponsor
- Fudan University
Endometrioid Endometrial Cancer
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer
- Trial name
- NCT06561308
- Testing
- Camrelizumab, Carboplatin, Paclitaxel
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
This is a phase Ib trial with SAR439459, a TGF-beta inhibitor, in combination with cemiplimab, a PD-L1 inhibitor, in patients with solid tumors that have spread to other places in the body (advanced) or cannot be removed by…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04729725
- Testing
- Anti-TGF-beta Monoclonal Antibody SAR-439459, Cemiplimab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Malignant Melanoma
Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis
This multicenter, retrospective observational study aims to identify clinical, pathological, and molecular factors associated with prognosis and treatment response in patients with metastatic malignant melanoma.
- Trial name
- MEL-CARE (NCT07256184)
- Testing
- Systemic Therapy for Metastatic Melanoma
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 232 people
- Sponsor
- Ankara Etlik City Hospital
Melanoma Stage III, Melanoma Stage IV
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
- Trial name
- NCT04139902
- Testing
- Dostarlimab (TSR-042) (singly), Dostarlimab (TSR-042) and TSR-022 (combination)
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Diwakar Davar
Stomach Neoplasms, Immune Checkpoint Inhibitors
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
This is a multicenter, randomized, phase 2 trial to investigate the efficacy and safety of serlulimab combined with nab-paclitaxel plus SOX versus nab-paclitaxel plus SOX alone as neoadjuvant treatment for locally advanced GC or…
- Trial name
- NCT06576921
- Testing
- Serplulimab Combined With Chemotherapy
- Where
- 5 sites in China
- Volunteers
- 116 people
- Sponsor
- Xijing Hospital
Renal Cell Carcinoma
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
The NESCIO-trial is a multicenter, randomized, open-label, three-arm phase II trial investigating different combinations of neoadjuvant immunotherapy in patients with primary, resectable, intermediate to high-risk, clear-cell…
- Trial name
- NESCIO (NCT05148546)
- Testing
- Neoadjuvant nivolumab, Neoadjuvant ipilimumab, Neoadjuvant relatlimab
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 69 people
- Sponsor
- The Netherlands Cancer Institute
Multiple Primary Lung Cancer
Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
Prospective, multi-center, phase II clinical trial. The study plans to enroll 146 patients with multiple lung cancers. After signing the informed consent, they were screened to meet the admission and discharge criteria, and…
- Trial name
- MAGIC (NCT05053802)
- Testing
- Microwave ablation plus Camrelizumab, Microwave ablation
- Where
- 6 sites in China
- Volunteers
- 146 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Neoplasms
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
This is a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of niraparib alone and in combination with PD-1 inhibitors in participants with locally advanced and metastatic non-small cell lung cancer…
- Trial name
- NCT03308942
- Testing
- Niraparib, Pembrolizumab, TSR-042 (Dostarlimab)
- Where
- 16 sites in United States
- Volunteers
- 53 people
- Sponsor
- Tesaro, Inc.
Oligometastasis, Lung Neoplasms
Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer
The study aim to investigator the efficacy and safety of sintilimab after Stereotactic Ablation Brachytherapy(SABT) for refractory oligometastatic non-small cell lung cancer(NSCLC), who had failed second-line systemic therapy.
- Trial name
- NCT04486287
- Testing
- Sintilimab
- Volunteers
- 44 people
- Sponsor
- Tianjin Medical University Second Hospital
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
This randomized phase II trial will characterize the efficacy, adverse event (AE) profile, and safety of two regimens of 5-FU given as 2L+ treatment to patients with RM-HNSCC.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT07419464
- Testing
- 5-Fluorouracil
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Washington University School of Medicine
Rectal Cancer
Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer
To increase the efficacy of neoadjuvant PD-1/PD-1 checkpoint inhibitor in local advanced rectal cancer (LARC), we propose preoperative arterial infusion of Tirellizumab and oxaliplatin followed by tumor artery embolization with…
- Trial name
- NCT05957016
- Testing
- CIETAI-R
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Third Military Medical University
Endometrial Cancer, Endometrioid Carcinoma
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial…
- Conditions
- Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency
- Trial name
- NCT06549855
- Testing
- Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University People's Hospital
Colorectal Cancer, Immunotherapy
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
This study is intended to evaluate efficacy and safety of the combination of regorafenib and nivolumab as third-line or later therapy in patients with microsatellite stable (MSS) colorectal cancer (CRC).
- Trial name
- NCT04110093
- Testing
- Regorafenib and PD-1 inhibitor
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Changzheng Hospital
Colorectal Cancer
RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer
As an established therapeutic target, HER2 is widely used in a variety of tumors, including breast cancer and gastric cancer, among which a variety of drugs, including trastuzumab, lapatinib and T-DM1, have been approved for the…
- Trial name
- DETECT (NCT05578287)
- Testing
- Anti-HER2 ADC
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-sen University